טוען...
Adaptive randomized phase II design for biomarker threshold selection and independent evaluation
BACKGROUND: Frequently a biomarker capable of defining a patient population with enhanced response to an experimental agent is not fully validated with a known threshold at the start of a phase II trial. When such candidate predictive markers are evaluated and/or validated retrospectively, over-accr...
שמור ב:
| הוצא לאור ב: | Chin Clin Oncol |
|---|---|
| Main Authors: | , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2014
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4255950/ https://ncbi.nlm.nih.gov/pubmed/25485277 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2304-3865.2013.12.04 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|